Pattern of regional cortical grey matter thickness and relationship to disability in RRMS patients treated with fingolimod
ECTRIMS Online Library. Kakara M. 09/13/19; 278528; P1326
Mihir Kakara
Mihir Kakara
Contributions
Abstract

Abstract: P1326

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - Biomarkers

M. Kakara, D. Chaar, S. Razmjou, F. Bao, C. Martinez, E. Bernitsas

Department of Neurology, Wayne State University School of Medicine, Detroit, MI, United States

Introduction: Cortical grey matter atrophy in relapsing-remitting multiple sclerosis(RRMS) is well documented, but the pattern of regional atrophy, and its relationship with disability has been unclear. Regional cortical atrophy, in relation to disability, in a homogeneously treated population as part of a longitudinal study with advanced imaging has been evaluated in very few studies.
Aim: To conduct a comprehensive assessment of imaging biomarkers that can predict disability and cognitive status in a longitudinal study of RRMS patients being treated with fingolimod.
Objectives: To assess relationship between regional grey matter cortical thickness and disability, and to identify specific regions that can predict worse Expanded Disability Status Scale(EDSS).
Methods: Cross-sectional data of 50 patients with RRMS on fingolimod, who were part of a prospective study were assessed at 24 months into the study. Cortical thickness from MRI was measured with FreeSurfer software and disability with EDSS. Pearson's partial correlation, corrected for age and disease duration, and multiple regression analysis were used for data analysis(IBM SPSS,v25).
Results: Thirty-two of the 50 patients were women. Mean age of the cohort was 41.1(SD=10.12) years and mean disease duration was 8.46(SD=6.62) years. Mean EDSS was 2.69(SD=2.16, 0-6.5). Strongest correlations with EDSS were seen in bilateral paracentral lobules (r=-0.6,p< 0.001), precentral gyri (r=-0.582, p< 0.0001), inferior temporal gyri (r=-0.591,p< 0.001), fusiform gyri(r=-0.526,p< 0.001), transverse temporal gyri(r=-0.540, p< 0.001), posterior cingulate cortex(r=-0.52,p< 0.001), rostral medial frontal area (r=-0.458,p=0.001) and supramarginal gyri(r=-0.427,p=0.001). Multiple regression analysis produced a significant equation(r2=0.836, F(25,17)=3.460,p=0.005), and indicated that paracentral lobules (β=-0.561,t=-2.19,p=0.043) and isthmus of cingulate gyrus (β=-0.7, t=-2.96, p=0.009) significantly predicted EDSS.
Conclusions: This study shows a strong relationship of physical disability to thickness of specific cortical regions in RRMS patients. As EDSS is more sensitive to motor impairment, there might be a preferential stronger correlation to precentral gyrus and paracentral lobules, but temporal lobe subregions have a strong correlation in advanced MS patients as well. Future directions include longitudinal analyses of data, correlating cognitive function, and larger prospective studies to validate our findings.
Disclosure: Mihir Kakara: Nothing to disclose
David Chaar: Nothing to disclose
Sara Razmjoui: Nothing to disclose
Fen Bao: Nothing to disclose
Carla Martinez: Nothing to disclose
Evanthia Bernitsas: I have received grants/consulting fees by Roche-Genetech, Sanofi-Genzyme, Chugai, Medimmune, Biogen, Celgene.

Abstract: P1326

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - Biomarkers

M. Kakara, D. Chaar, S. Razmjou, F. Bao, C. Martinez, E. Bernitsas

Department of Neurology, Wayne State University School of Medicine, Detroit, MI, United States

Introduction: Cortical grey matter atrophy in relapsing-remitting multiple sclerosis(RRMS) is well documented, but the pattern of regional atrophy, and its relationship with disability has been unclear. Regional cortical atrophy, in relation to disability, in a homogeneously treated population as part of a longitudinal study with advanced imaging has been evaluated in very few studies.
Aim: To conduct a comprehensive assessment of imaging biomarkers that can predict disability and cognitive status in a longitudinal study of RRMS patients being treated with fingolimod.
Objectives: To assess relationship between regional grey matter cortical thickness and disability, and to identify specific regions that can predict worse Expanded Disability Status Scale(EDSS).
Methods: Cross-sectional data of 50 patients with RRMS on fingolimod, who were part of a prospective study were assessed at 24 months into the study. Cortical thickness from MRI was measured with FreeSurfer software and disability with EDSS. Pearson's partial correlation, corrected for age and disease duration, and multiple regression analysis were used for data analysis(IBM SPSS,v25).
Results: Thirty-two of the 50 patients were women. Mean age of the cohort was 41.1(SD=10.12) years and mean disease duration was 8.46(SD=6.62) years. Mean EDSS was 2.69(SD=2.16, 0-6.5). Strongest correlations with EDSS were seen in bilateral paracentral lobules (r=-0.6,p< 0.001), precentral gyri (r=-0.582, p< 0.0001), inferior temporal gyri (r=-0.591,p< 0.001), fusiform gyri(r=-0.526,p< 0.001), transverse temporal gyri(r=-0.540, p< 0.001), posterior cingulate cortex(r=-0.52,p< 0.001), rostral medial frontal area (r=-0.458,p=0.001) and supramarginal gyri(r=-0.427,p=0.001). Multiple regression analysis produced a significant equation(r2=0.836, F(25,17)=3.460,p=0.005), and indicated that paracentral lobules (β=-0.561,t=-2.19,p=0.043) and isthmus of cingulate gyrus (β=-0.7, t=-2.96, p=0.009) significantly predicted EDSS.
Conclusions: This study shows a strong relationship of physical disability to thickness of specific cortical regions in RRMS patients. As EDSS is more sensitive to motor impairment, there might be a preferential stronger correlation to precentral gyrus and paracentral lobules, but temporal lobe subregions have a strong correlation in advanced MS patients as well. Future directions include longitudinal analyses of data, correlating cognitive function, and larger prospective studies to validate our findings.
Disclosure: Mihir Kakara: Nothing to disclose
David Chaar: Nothing to disclose
Sara Razmjoui: Nothing to disclose
Fen Bao: Nothing to disclose
Carla Martinez: Nothing to disclose
Evanthia Bernitsas: I have received grants/consulting fees by Roche-Genetech, Sanofi-Genzyme, Chugai, Medimmune, Biogen, Celgene.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies